References
- Palumbo A, Bringhen S, Liberati AM, et al Oral melphalan, prednisone and thalidomide in elderly patients with multiple myeloma: update results of a randomized controlled trial. Blood 2008;112:3107–3114.
- Facon T, Mary JY, Hulin C, et al Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209–1218.
- Hulin C, Facon T, Rodon P, et al Efficacy of melphalan and prednisone plus thalidomide patients older than 75 years with newly diagnosed multiple myeloma: IFM01/01 trial. J Clin Oncol 2009;27:3664–3670.
- Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000;5:224–237.
- de Weerdt O, van de Donk NW, Veth G, et al Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth J Med 2001;59:50–56.
- Trieu Y, Trudel S, Pond GR, et al Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. Mayo Clin Proc 2005;80:1578–1582.
- Kropff M, Bisping G, Liebisch P, et al Bortezomib in combination with high-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Blood 2005;106(Suppl. 1):716a (Abstract 2549).
- Richardson PGG, Barlogie B, Berenson J, et al Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005;106:2977–2981.
- San Mighel JF, Schlag R, Khuageva NK, et al Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–917.
- Oakervee HE, Popat R, Curry N, et al PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005;129:755–762.
- Reece DE, Piza Rodriguez G, Chen C, et al Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008;26:4777–4783.
- Durie Brian GM, Salmon Sydney E. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36:842–854.